First exosome-based liquid biopsy test receives FDA’s breakthrough device designation

June 19, 2019 Leave a comment 2,247 Views

Bio-Techne today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its ExoDx Prostate IntelliScore (EPI) test, making it the first exosome-based liquid biopsy test to receive a Breakthrough Device Designation. This designation not ...

Exosome RNA Exosome RNA Research & Industry News

Tag Archives: U.S. Food and Drug Administration

First exosome-based liquid biopsy test receives FDA’s breakthrough device designation

Identification of a novel RNA aptamer that selectively targets breast cancer exosomes

Capricor Therapeutics Announces Publication Demonstrating Methods for Enhanced Potency of Cardiosphere-Derived Exosomes

Functional single-cell profiling identifies that exosomes are associated with increased immune cell infiltration in non-metastatic breast cancer

Liquid biopsy-based exo-oncomiRNAs can predict prostate cancer aggressiveness

The body’s own signalling system provides the key to new diagnostic tools and personalized medicine

FT-IR spectroscopy to show alterations in molecular composition of EV subpopulations from melanoma cell lines in different malignancy